A recent study in Molecular Psychiatry has unveiled a pivotal revelation—cannabis alters DNA methylation, leaving a lasting imprint on our genetic makeup. As the world witnesses an upsurge in cannabis use, both medicinal and recreational, this study ventures beyond the known effects, delving into the intricate realm of peripheral blood methylation.
Decoding DNA Methylation in Cannabis Users
DNA methylation, a key indicator of environmental impacts on health, takes center stage in this study. With the widespread legalization of cannabis, its therapeutic benefits have been extensively studied. However, the focus here extends to recreational use, raising concerns about addiction, cognitive deficits, and mental health disorders. The study zeroes in on the intricate dance between cannabis use and changes in DNA methylation, specifically in peripheral blood.
Research Methods and Cohort Diversity
Building on previous methodologies, the researchers conducted a large-scale epigenome-wide association study (EWAS) using peripheral blood samples. The study cohort, diverse in its composition, included twins, older adults, parents and children, and adult twins. With 9,436 participants, the study carefully examined the association between lifetime cannabis use and DNA methylation patterns. Adjusting for various factors like age, sex, and smoking behavior, the study offers a comprehensive exploration of this genetic interplay.
CpG Sites and Overlapping Traits
The study’s findings identified four significant CpG sites associated with cannabis use, independent of cigarette smoking. Remarkably, these sites did not overlap with known cigarette smoking-related sites. Further analysis in participants who never smoked cigarettes revealed additional CpG sites. Intriguingly, these CpG sites exhibited significant overlap with those linked to Crohn’s disease, alcohol consumption, body mass index (BMI), and multiple sclerosis, broadening the spectrum of potential health impacts.
Genetic Insights and Health Outcomes
Delving into the genetics, the study uncovered five genes containing DNA-methylated CpG sites associated with cannabis use. From oncogenic functions to links with diseases like hepatocellular carcinoma, Angelman syndrome, and COVID-19, these genes play pivotal roles in health outcomes. Despite this genetic complexity, the study found no significant influence of genetic variants on the observed DNA methylation changes.
Implications for the Life Science Industry
The study’s insights hold profound implications for drug manufacturers in the life science industry. As cannabis-related research transcends traditional boundaries, pharmaceutical and biotechnology sectors can harness these findings to inform investigations into the nuanced impacts on altered DNA states. The identified CpG sites may serve as markers not only for cannabis-related concerns but also as key indicators for broader health implications.
This study marks a significant stride in understanding the intricate interplay between cannabis use, DNA-methylation in peripheral blood, and broader health outcomes. While offering crucial insights into shared DNA methylation profiles, it beckons the scientific community to dive deeper. Drug manufacturers are urged to seize this opportunity, incorporating these findings into their research agendas, unlocking potential therapeutic avenues and broadening our comprehension of the genetic impacts of cannabis. As the journey continues, a call to action resonates — please let the pursuit of knowledge be relentless, collaborative, and transformative, as we navigate the uncharted territories of bioinformatics!
Outsourcing Bioinformatics Analysis: How Bridge Informatics Can Help
BI’s data scientists prioritize studying, understanding, and reporting on the latest developments so we can advise our clients confidently. The generation, storage and analysis of biological data is faster and more accessible than ever before. From pipeline development and software engineering to deploying your existing bioinformatic tools, Bridge Informatics can help you on every step of your research journey.
As experts across data types from leading sequencing platforms, we can help you tackle the challenging computational tasks of storing, analyzing and interpreting genomic and transcriptomic data. Bridge Informatics’ bioinformaticians are trained bench biologists, so they understand the biological questions driving your computational analysis. Click here to schedule a free introductory call with a member of our team.
Haider M. Hassan, Data Scientist, Bridge Informatics
Haider is one of our premier data scientists. He provides bioinformatic services to clients, including high throughput sequencing, data pre-processing, analysis, and custom pipeline development. Drawing on his rich experience with a variety of high-throughput sequencing technologies, Haider analyzes transcriptional (spatial and single-cell), epigenetic, and genetic landscapes.
Before joining Bridge Informatics, Haider was a Postdoctoral Associate at the London Regional Cancer Centre in Ontario, Canada. During his postdoc, he investigated the epigenetics of late-onset liver cancer using murine and human models. Haider holds a Ph.D. in biochemistry from Western University, where he studied the molecular mechanisms behind oncogenesis. Haider still lives in Ontario and enjoys spending his spare time visiting local parks. If you’re interested in reaching out, please email [email protected] or [email protected]